This is a non-interventional, retrospective observational study using existing data from patient medical records. The study will include mCRPC patients previously treated with taxanes who initiated treatment with 177[Lu]Lu-PSMA-I&T at selected Oncological Centres. The study’s observation period will start from the earliest recorded 177[Lu]Lu-PSMA-I&T treatment and will run until February 29, 2024.
